RECARDIO at the BIO 2025 International Convention
- haraldkattnig5
- 2 days ago
- 1 min read
San Francisco, June 03, 2025 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced that is participating in the international exhibition at the 2025 BIO International Convention in Boston, USA.
The convention is the world’s largest advocacy association representing biotechnology companies, academic and research institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
The conference is taking place on June 16 – 19, 2025 in Boston.
Recardio is participating and presenting its portfolio and taking advantage of the opportunity for global networking, partnering and lead generation for companies around the world.
About Recardio
Recardio Inc. is a late-stage clinical life science company focusing on therapies for cardiovascular and other diseases.
 The company is located in San Francisco, California, having its operations in USA and Europe.
The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated pre- and clinically significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration resulting in healing cardiac tissue after an injury.
After receiving FDA and EMA approval, Recardio is currently preparing its global pivotal Phase 3 clinical program in acute myocardial infarction for market authorization in major markets and will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases.
In addition, other development programs are in earlier clinical and preclinical stage.
For more information, visit: http://www.recardio.eu/Â or contact pr@recardio.eu